Work Here?
Work Here?
Work Here?
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Total Funding
$102.1M
Headquarters
Cambridge, Massachusetts
Founded
2014
Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like amyotrophic lateral sclerosis (ALS). Their approach involves using a proprietary platform that utilizes adeno-associated virus (AAV) capsids to deliver genetic material directly to the brain through intravenous dosing, overcoming the challenge of the blood-brain barrier. Unlike many competitors, Voyager focuses on creating treatments that are specifically designed to address severe neurological conditions, and they emphasize collaboration with larger pharmaceutical companies to enhance their research and development efforts. The company's goal is to provide transformative therapies that significantly improve the lives of patients suffering from these debilitating diseases.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$102.1M
Above
Industry Average
Funded Over
4 Rounds
Flexible Work Hours
Additionally, Voyager will participate in the Stifel 2025 Virtual CNS Forum, featuring a fireside chat on March 19, 2025, at 11:00 a.m. ET.
At the start of 2024, Voyager Therapeutics announced that it would collaborate with Novartis to discover and develop next-generation gene therapies for SMA and other neurologic conditions.
Great Point Partners LLC invests $12.67 million in Voyager Therapeutics, Inc. (NASDAQ:VYGR).
Voyager Therapeutics appoints Nathan Jorgensen as Chief Financial Officer.
Improving Gene TherapyIn December 2023, the FDA made history by approving the first human gene therapy for sickle cell disease. This was quite a revolution and opened the way for much more gene therapy for other incurable diseases.One difficulty in all gene therapy procedures is getting enough of the intended genetic material delivered into the target cells. This can cause multiple issues, from too low gene modification to be efficient as a medicine to un-targeted cells being modified or immune reactions and side effects from too concentrated a dose. And, of course, using more than needed gene editing medicine is expensive.Luckily, researchers might have found a way to solve this issue, using electric pulses to boost the efficiency of gene transformation 40 times.Electricity For Gene EditingUsing electricity for gene modification is not really a new concept in itself, with electroporation a very ancient method used to create GMOs. However, in the case of this method, the damage inflicted on the cells by the very high voltage makes it only fit for modifying cell culture, bacteria, or plants, and not the gene inside a living animal or human.What the researchers at the University of WisconsinâMadison have discovered is that gene therapies can be improved with a short pulse of electricity instead. This was done in collaboration between University of WisconsinâMadison researchers ( Susan Hagness and John Booske and PhD student Yizhou Yao) and Hans Sollinger, a world-renowned transplant surgeon.Contrary to the more brutal electroporation method, the electric pulses are very quick, only 80 milliseconds long
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Total Funding
$102.1M
Headquarters
Cambridge, Massachusetts
Founded
2014
Find jobs on Simplify and start your career today